Ryvu Therapeutics 미래 성장

Future 기준 확인 1/6

Ryvu Therapeutics 의 수익은 연간 10.1% 감소할 것으로 예상되는 반면, 연간 수익은 19.3% 로 증가할 것으로 예상됩니다. 19.3% 연간. EPS는 연간 3.3% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -125.8% 로 예상됩니다.

주요 정보

-10.1%

수익 성장률

-3.3%

EPS 성장률

Life Sciences 수익 성장	26.0%
매출 성장률	19.3%
향후 자기자본 수익률	-125.8%
애널리스트 커버리지	Low
마지막 업데이트	23 Dec 2024

최근 미래 성장 업데이트

Recent updates

The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More

Dec 07

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Oct 20

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Aug 02

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Jan 25

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Feb 05

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

Dec 14

수익 및 매출 성장 예측

WSE:RVU - 애널리스트의 미래 추정치 및 과거 재무 데이터 (PLN Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	190	-140	-218	-132	3
12/31/2025	150	-101	-185	-98	3
12/31/2024	100	-104	-106	-100	3
9/30/2024	91	-104	-132	-121	N/A
6/30/2024	82	-96	-102	-92	N/A
3/31/2024	74	-94	-103	-95	N/A
12/31/2023	67	-92	-93	-85	N/A
9/30/2023	84	-73	-6	0	N/A
6/30/2023	88	-66	-2	3	N/A
3/31/2023	80	-75	4	10	N/A
12/31/2022	68	-84	15	21	N/A
9/30/2022	50	-94	-51	-44	N/A
6/30/2022	37	-105	-68	-58	N/A
3/31/2022	36	-92	-80	-69	N/A
12/31/2021	35	-79	-71	-59	N/A
9/30/2021	26	-72	-74	-58	N/A
6/30/2021	25	-61	-61	-37	N/A
3/31/2021	30	-41	-38	-5	N/A
12/31/2020	37	-32	-45	-11	N/A
9/30/2020	38	-40	-57	-23	N/A
6/30/2020	41	-32	-74	-51	N/A
3/31/2020	17	-41	-36	-17	N/A
12/31/2019	34	-44	-41	-17	N/A
9/30/2019	53	-53	-55	-27	N/A
6/30/2019	19	-60	-38	-6	N/A
3/31/2019	116	-28	-77	-49	N/A
12/31/2018	52	-23	-44	-26	N/A
9/30/2018	49	2	-22	-7	N/A
6/30/2018	96	14	N/A	-4	N/A
3/31/2018	102	21	N/A	22	N/A
12/31/2017	105	6	N/A	11	N/A
9/30/2017	104	13	N/A	7	N/A
6/30/2017	97	14	N/A	8	N/A
3/31/2017	80	10	N/A	-24	N/A
12/31/2016	66	3	N/A	-6	N/A
9/30/2016	60	0	N/A	-6	N/A
6/30/2016	60	-1	N/A	-10	N/A
3/31/2016	57	3	N/A	-14	N/A
12/31/2015	56	6	N/A	-16	N/A
9/30/2015	51	7	N/A	-10	N/A
6/30/2015	48	7	N/A	-8	N/A
3/31/2015	46	7	N/A	-5	N/A
12/31/2014	41	6	N/A	-5	N/A
9/30/2014	43	4	N/A	-6	N/A
6/30/2014	35	2	N/A	-5	N/A
3/31/2014	27	-1	N/A	-6	N/A
12/31/2013	22	-2	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: RVU 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: RVU 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: RVU 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: RVU 의 수익(연간 19.3% ) Polish 시장( 5% 보다 빠르게 성장할 것으로 예상됩니다. 5% 연간).

고성장 수익: RVU 의 수익(연간 19.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: RVU (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 16:49
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Ryvu Therapeutics S.A. 9 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Kamil Kliszcz	Biuro maklerskie mBanku
Beata Szparaga-Wasniewska	Biuro maklerskie mBanku
Jonas Peciulis	Edison Investment Research

Ryvu Therapeutics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 19% to zł65.83

Price target increased by 8.5% to zł77.95

Price target increased by 13% to zł72.23

Price target increased by 8.7% to zł63.80

Recent updates

Price target decreased by 19% to zł65.83

Ryvu Therapeutics provides an update on RVU120 Phase II program

The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More

Ryvu Therapeutics Announces Dosing of the First Patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Third quarter 2024 earnings released: zł1.10 loss per share (vs zł0.79 loss in 3Q 2023)

Ryvu Therapeutics Announces Dosing of the First Patient in the Remark Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

New major risk - Financial position

Second quarter 2024 earnings released: zł1.40 loss per share (vs zł1.23 loss in 2Q 2023)

Price target increased by 8.5% to zł77.95

Ryvu Therapeutics S.A., Annual General Meeting, Jun 27, 2024

First quarter 2024 earnings released: zł0.80 loss per share (vs zł0.79 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics Announces Dosing of the First Patient in the River-81 Phase Ii Study of Rvu120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory Aml

Ryvu Therapeutics S.A. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Share price stability

Ryvu Therapeutics S.A. Presents Data on Rvu120 At the San Antonio Breast Cancer Symposium 2023

Third quarter 2023 earnings released

Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120

Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt

Second quarter 2023 earnings released

New major risk - Financial position

Ryvu Therapeutics S.A., Annual General Meeting, Jun 14, 2023

First quarter 2023 earnings released

Price target increased by 13% to zł72.23

Price target increased by 8.7% to zł63.80

Ryvu Therapeutics S.A. to Report Q3, 2023 Results on Nov 29, 2023

Ryvu Therapeutics S.A. Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics S.A. Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

Ryvu Therapeutics S.A. announced that it expects to receive PLN 1.9 million in funding

Ryvu Therapeutics S.A. announced that it has received €22 million in funding from European Investment Bank, Investment Arm

We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate

Ryvu Therapeutics Announces Executive Changes

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics S.A., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 At the 2022 European Hematology Association Congress

Ryvu Therapeutics Announces Project Updates at the 2022 American Society of Clinical Oncology Annual Meeting

Full year 2021 earnings: Revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?

Now 20% undervalued after recent price drop

Ryvu Therapeutics S.A. Presents Clinical and Translational Data Updates At the 63rd American Society of Hematology Annual Meeting and the 44Th San Antonio Breast Cancer Symposium

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Ryvu Therapeutics S.A. Announces First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors

Ryvu Therapeutics S.A. Announces FDA Lifts Partial Clinical Hold on Phase IB Clinical Trial of RVU120 in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Ryvu Therapeutics Presents Positive Phase I Data for Rvu120 of Phase I/Ii Data for Sel24 Presented by Development Partner Menarini

Ryvu Therapeutics Announces Results SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

Ryvu Therapeutics S.A. Got Full Approval to Conduct Phase I/Ii Study of Rvu120 (Sel120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors in Poland

First quarter 2021 earnings released

Ryvu Therapeutics S.A. to Present Clinical and Translational Data from RVU120 at the Virtual 26th Annual Congress of the European Hematology Association

Full year 2020 earnings released

Ryvu Signs a Deal for Phase I Clinical Trials for its RVU120 Drug

What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?

Ryvu Therapeutics S.A. to Report First Half, 2021 Results on Sep 08, 2021

Ryvu Therapeutics S.A. to Report Q3, 2021 Results on Nov 10, 2021

Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return

New 90-day low: zł49.00

New 90-day low: zł52.00

First half earnings released

New 90-day low: zł58.80

Ryvu Therapeutics S.A. Announces That the First Patient Has Been Treated in Europe for the Cohort Expansion Part of Phase Ii Diamond-01 Clinical Trial (Cli24-001; Nct03008187)

New 90-day low - zł60.00

Ryvu Therapeutics S.A. has completed a Follow-on Equity Offering in the amount of PLN 143.0547 million.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측